Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SCN2B | O60939 | 1/20 | 0.30 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879034 | 1.00 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11TYMP | |
| SCHEMBL4876312 | 0.86 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL4876311 | 0.86 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL4877851 | 0.85 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL4871335 | 0.80 | HTR1A (0.34) | MAPK14MAPK13MAPK12MAPK11TP53 | |
| SCHEMBL4875278 | 0.80 | KMT2A (0.40) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL4871343 | 0.80 | HTR1A (0.34) | MAPK14MAPK13MAPK12MAPK11TP53 | |
| SCHEMBL4875287 | 0.80 | KMT2A (0.40) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL4879463 | 0.79 | SYK (0.36) | MAPK14TP53KMT2A | |
| SCHEMBL4879459 | 0.79 | SYK (0.36) | MAPK14TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | MAPK14 13/4885MAPK13 12/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.